GlassScriptPhysician profile
Stephanie Fox
NPI 1629062708
$2,546.04
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $443 · 2022: $1,116 · 2023: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $986.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $395.71 | 2022-2023 | Trudhesa |
| Teva Pharmaceuticals USA, INC. | $229.03 | 2021-2022 | |
| Viiv Healthcare Company | $227.53 | 2022 | |
| Coloplast Corp | $220.26 | 2023 | Titan, Altis |
| Boston Scientific Corporation | $193.07 | 2023 | |
| Janssen Pharmaceuticals, INC | $135.00 | 2022 | |
| Urovant Sciences INC | $123.92 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.64 | 2023 | |
| Lilly USA, LLC | $121.87 | 2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.98 | 2022 | |
| Genentech USA, INC. | $111.38 | 2021 | |
| Neurocrine Biosciences, INC. | $109.59 | 2023 | |
| Abbvie INC. | $106.86 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.56 | 2021 | |
| Alkermes, INC. | $79.38 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $75.62 | 2022 | |
| Glaxosmithkline, LLC. | $73.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.